0001213900-26-052920
SEC filingQ3 FY2026 net loss widened 39.9% YoY to -$3.0M as R&D expenses increased due to higher external contractor and research supply costs, though diluted EPS improved 62.4% to -$0.73 on lower shares outstanding; operating cash burn eased slightly to -$5.7M amid ongoing negative flows and no committed capital.
InMed Pharmaceuticals Inc. reported a GAAP net loss of -$3.0 million for Q3 FY2026 ended March 31, 2026, representing a 39.9% year-over-year widening from -$2.1 million in the prior-year quarter. This deterioration occurred as research and development expenses rose, primarily due to higher external contractor and research supply costs—a key driver noted in management's discussion. These external costs represent a significant portion of R&D spending, tracked on a program-by-program basis following development candidate nomination, underscoring the company's focus on advancing its pipeline despite financial pressures.
Diluted EPS showed improvement at -$0.73, a 62.4% enhancement from -$1.94 YoY. This per-share progress stems from dynamics in weighted average shares outstanding, mitigating the impact of the larger absolute loss and providing a more favorable metric for investors tracking operational efficiency on a diluted basis.
Cash flow from operations reflected ongoing challenges, with net cash used totaling -$5.7 million in the quarter, a modest improvement from -$6.0 million YoY. Management attributes persistent negative cash flows to the company's operational profile since inception, where revenue has come exclusively from BayMedica product sales with no other sources. The slight moderation in burn rate suggests some working capital efficiencies, though the business model continues to generate significant cash outflows.
Liquidity remains precarious, as the company discloses no credit facility or committed sources of capital. This absence amplifies risks around funding pipeline advancement and general operations, consistent with historical patterns of operating losses. General and administrative expenses also contributed to the net loss expansion, with management noting increases primarily from higher salaries and benefits, alongside impacts from lower gross profit in the period.
Overall, these results reflect a strategic emphasis on R&D amid a revenue-constrained environment tied to BayMedica. Investors should note that actual results may vary materially if risks materialize or assumptions prove incorrect, as highlighted in market risk disclosures. The focus on external R&D contractors signals progress toward potential milestones, but sustained losses and cash usage necessitate careful monitoring of capital access.